Nasal Immunization With Small Molecule Mast Cell Activators Enhance Immunity to Co-Administered Subunit Immunogens
Open Access
- 10 September 2021
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 12, 730346
- https://doi.org/10.3389/fimmu.2021.730346
Abstract
Mast cell activators are a novel class of mucosal vaccine adjuvants. The polymeric compound, Compound 48/80 (C48/80), and cationic peptide, Mastoparan 7 (M7) are mast cell activators that provide adjuvant activity when administered by the nasal route. However, small molecule mast cell activators may be a more cost-efficient adjuvant alternative that is easily synthesized with high purity compared to M7 or C48/80. To identify novel mast cell activating compounds that could be evaluated for mucosal vaccine adjuvant activity, we employed high-throughput screening to assess over 55,000 small molecules for mast cell degranulation activity. Fifteen mast cell activating compounds were down-selected to five compounds based on in vitro immune activation activities including cytokine production and cellular cytotoxicity, synthesis feasibility, and selection for functional diversity. These small molecule mast cell activators were evaluated for in vivo adjuvant activity and induction of protective immunity against West Nile Virus infection in BALB/c mice when combined with West Nile Virus envelope domain III (EDIII) protein in a nasal vaccine. We found that three of the five mast cell activators, ST101036, ST048871, and R529877, evoked high levels of EDIII-specific antibody and conferred comparable levels of protection against WNV challenge. The level of protection provided by these small molecule mast cell activators was comparable to the protection evoked by M7 (67%) but markedly higher than the levels seen with mice immunized with EDIII alone (no adjuvant 33%). Thus, novel small molecule mast cell activators identified by high throughput screening are as efficacious as previously described mast cell activators when used as nasal vaccine adjuvants and represent next-generation mast cell activators for evaluation in mucosal vaccine studies.Funding Information
- National Institute of Allergy and Infectious Diseases
This publication has 97 references indexed in Scilit:
- Mechanisms of Action of AdjuvantsFrontiers in Immunology, 2013
- STAR: ultrafast universal RNA-seq alignerBioinformatics, 2012
- MHC class II distribution in dendritic cells and B cells is determined by ubiquitin chain lengthProceedings of the National Academy of Sciences of the United States of America, 2012
- Intranasal Immunization of Ferrets with Commercial Trivalent Influenza Vaccines Formulated in a Nanoemulsion-Based AdjuvantClinical and Vaccine Immunology, 2011
- Preliminary evaluation of a 3H imidazoquinoline library as dual TLR7/TLR8 antagonistsBioorganic & Medicinal Chemistry, 2011
- Principles of early drug discoveryBritish Journal of Pharmacology, 2011
- Effective induction of protective systemic immunity with nasally administered vaccines adjuvanted with IL-1Vaccine, 2010
- Integration of Small-Molecule Discovery in Academic Biomedical ResearchMount Sinai Journal of Medicine: A Journal of Translational and Personalized Medicine, 2010
- Mast Cells Augment Adaptive Immunity by Orchestrating Dendritic Cell Trafficking through Infected TissuesCell Host & Microbe, 2009
- Mast cell–derived tumor necrosis factor induces hypertrophy of draining lymph nodes during infectionNature Immunology, 2003